Of note, four (26.7%) patients had either hormone receptor+/HER2‐ breast cancer (n = 3) or hormone receptor+/HER2+ breast cancer (n = 1) at the initial diagnosis, which then changed to TNBC at recurrence or during the course of treatment for metastatic disease. Here, ERBB2 is linked to breast carcinoma.